US EditionAstraZeneca affirms commitment to US manufacturing as profits rise
- AstraZeneca is committed to investing and growing in the US, stating, "Our company is firmly committed to investing and growing in the US."
- The company plans to invest $3.5 billion in the US by the end of 2026, as it is a key market for the pharmaceutical industry.
- AstraZeneca hopes the US will account for around half of its global revenue by 2030.
- The company reaffirmed its target of achieving $80 billion in annual revenue by the end of the decade.
Insights by Ground AI
Does this summary seem wrong?
30 Articles
30 Articles
All
Left
2
Center
8
Right
4
Trump's trade war seems to be biting: European pharmaceutical companies are now investing heavily in the United States
The EU has sought to strengthen Europe's own pharmaceutical production. However, now pharmaceutical companies are investing in the United States, in line with Trump's wishes.
·Finland
Read Full Article
NDTVReposted by 
UrduPoint
UrduPointAstraZeneca Moves Some Production To US Amid Tariff Threat
British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector.
·New Delhi, India
Read Full Article
Coverage Details
Total News Sources30
Leaning Left2Leaning Right4Center8Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
14%
C 57%
R 29%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
